Your browser doesn't support javascript.
loading
Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.
Schultz, Chad R; Swanson, Matthew A; Dowling, Thomas C; Bachmann, André S.
Affiliation
  • Schultz CR; Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, 400 Monroe Ave, NW, Grand Rapids, MI, 49503, USA.
  • Swanson MA; Shimadzu Core Laboratory for Academic and Research Excellence, Ferris State University, Big Rapids, MI, USA.
  • Dowling TC; Department of Pharmaceutical Sciences, College of Pharmacy, Ferris State University, Big Rapids, MI, USA.
  • Bachmann AS; Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, 400 Monroe Ave, NW, Grand Rapids, MI, 49503, USA. bachma26@msu.edu.
Cancer Chemother Pharmacol ; 88(4): 607-617, 2021 10.
Article in En | MEDLINE | ID: mdl-34129075
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Probenecid / Eflornithine / Neuroblastoma / Antineoplastic Agents Limits: Animals / Female / Humans Language: En Journal: Cancer Chemother Pharmacol Year: 2021 Document type: Article Affiliation country: United States Country of publication: Germany
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Probenecid / Eflornithine / Neuroblastoma / Antineoplastic Agents Limits: Animals / Female / Humans Language: En Journal: Cancer Chemother Pharmacol Year: 2021 Document type: Article Affiliation country: United States Country of publication: Germany